Background: HIV-infected patients with TB need simplified, effective and well-tolerated antiretroviral regimens.
Introduction
Co-infection with Mycobacterium tuberculosis and HIV is a major public health problem worldwide, 1 and TB is the most common AIDS-defining illness in many countries. An estimated 1.37 million new cases of TB occur each year in HIV-infected patients, mostly in Africa, and 25% of TB-related deaths involve HIV-infected patients. In addition, there is very limited decrease in TB incidence among patients having CD4 ,50 cells/mm 3 on a combination ART (cART) regimen. 2 Numerous pharmacokinetic interactions and additive toxicities have been reported between TB drugs and cART 3 -6 and the risk of an immune reconstitution inflammatory syndrome (IRIS) has been well documented. 7, 8 Finally, the need for close long-term adherence to both cART and TB therapy calls for simplified cART regimens. 9, 10 The ANRS 129 BKVIR non-comparative pilot trial was designed to evaluate the efficacy and safety of once-daily tenofovir DF/ emtricitabine and efavirenz, prescribed as a first-line combination ,12 weeks after starting antituberculous drugs in patients co-infected with HIV and TB. This trial also assessed rifampicin and isoniazid pharmacokinetics and the potential impact on TB outcome.
Patients and methods

Study design and population
The ANRS 129 BKVIR study was a multicentre, non-comparative, nationwide trial. HIV-1-infected, antiretroviral-naive adults were eligible if they had confirmed TB and had been treated with antituberculous drugs for ,12 weeks before inclusion. Patients had to be affiliated to the healthcare system and were not eligible if they had HIV-2 or group O infection or active cancer, were pregnant or breastfeeding, or had creatinine clearance ,60 mL/min, haemoglobin ,8 g/dL, neutrophils ,750/mm 3 , platelets ,50 000/mm 3 , or any liver enzyme value .3-fold higher than the upper normal limit.
All the patients gave their written informed consent and the protocol was approved by an ethics committee (Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale Paris Necker, France, number 05-06-09) and by the Agence Française de Sé curité Sanitaire des Produits de Santé . The trial conformed to the Declaration of Helsinki. This trial is registered with ClinicalTrials.gov (identifier: NCT00115609).
Study treatments
At week 0, all the patients started a once-daily cART regimen combining tenofovir DF (300 mg/day)/emtricitabine (200 mg/day) and efavirenz (800 mg/day if also treated with rifampicin, otherwise 600 mg/day). Antitubercular treatment was managed by the study investigators according to the standard of care (intensive phase followed by a continuation phase with duration depending on TB localization).
Primary and secondary outcome measures
The primary endpoint was a combination of HIV-1 RNA ,50 copies/mL and TB cure at week 48 ('combined success'). The choice of a combined outcome was based on a real-life approach, taking into account difficulties of compliance to multiple drugs. TB was considered 'probably cured' if all TB-attributed signs resolved and 'certainly cured' when, in addition, at least two sputum smears were negative (if TB had been diagnosed microscopically) or if culture was negative (in patients with positive culture at baseline). Secondary endpoints included changes in the plasma HIV-1 RNA level and CD4+ T cell count, changes in the HIV-1 DNA level, TB cure at week 48, adherence to treatment, pharmacokinetics of TB drugs, safety and IRIS.
Local laboratories measured HIV-1 RNA and CD4+ T cells at the screening visit, baseline (week 0) and weeks 4, 8, 12, 24, 36 and 48 . HIV-1 DNA was measured in peripheral blood mononuclear cells at weeks 0, 24 and 48.
11 Drug susceptibility testing (DST) was performed in each centre by using the proportion method, on either solid (Lö wenstein -Jensen) or liquid (MGIT) medium. DST quality was assessed by an external quality assessment programme using proficiency testing organized by the National Reference Laboratory. The average agreement rates for isoniazid and rifampicin DST were .90%.
Efavirenz plasma concentrations were measured at week 2 in patients treated with rifampicin. Concentrations were considered sub-therapeutic if ,1 mg/L and supra-therapeutic if .4 mg/L. Rifampicin and isoniazid trough and 2 h concentrations were measured at weeks 2, 8, 12 and 24 by liquid chromatography.
12 Low 2 h concentrations were defined as ,8 mg/L for rifampicin and ,3 mg/L for isoniazid, and very low 2 h concentrations as ,4 mg/L for rifampicin and ,2 mg/L for isoniazid. 13, 14 TB was evaluated by the investigators according to national guidelines. The severity of clinical and laboratory abnormalities was graded with the Agence Nationale de Recherches sur le SIDA et les Hé patites Virales (ANRS) scale.
Events Review Committee
An Events Review Committee (ERC) reviewed TB diagnoses and cures, as well as adverse events related or not related to the study drugs. IRIS cases were reviewed and classified. 15, 16 IRIS was also classified as definite, probable or ruled out.
Statistical analysis
Based on the literature available at the set-up of the trial, the success rate at week 48 was expected to be at least 55%. One hundred patients were required to ensure that the precision of the estimated success rate (twosided 95% CI) would be at least 10%. The primary analysis was conducted on an ITT basis and included all enrolled patients, regardless of whether or not the study treatment was prematurely discontinued. Missing HIV-1 RNA values were classified as treatment failures in the primary efficacy analysis. The primary endpoint was also analysed separately among patients who fully adhered to the trial strategy and among patients who did not comply with the therapeutic strategy.
Differences in continuous variables were assessed using the Wilcoxon rank-sum test. The cumulative incidence of events was estimated using the Kaplan-Meier method, from week 0 onwards.
Risk factors for IRIS were identified by logistic regression. Baseline characteristics with P values of ≤0.25 in univariable analysis were included in the multivariable model. Variables retained in the multivariable model were those associated with IRIS at a P value of ≤0.05.
All statistical analyses were performed with SAS software version 9.1.3 service pack 2 (SAS institute Inc., Cary, NC, USA). Drug concentrations were analysed with JMP version 5.0.1.2 (SAS institute Inc., Cary, NC, USA).
Results
From December 2005 to December 2008, 85 patients were screened, 70 were enrolled and 69 were analysed (one patient had no French healthcare coverage). Despite extension of the inclusion period, recruitment of the 100 participants needed was not achieved because of the lack of healthcare coverage in migrants with TB in France.
Four patients did not complete follow-up (one patient developed lymphoma and three were lost to follow-up) ( Figure 1 ).
Baseline characteristics at cART initiation
The time between diagnosis of HIV infection and cART initiation was ,3 months in 40 patients (58%). TB and HIV infections were diagnosed simultaneously in 71% of cases.
Extrapulmonary TB was found in 64 patients (93%). Samples were acid-fast bacilli-positive in 48 patients (70%). TB was confirmed by culture in 60 patients (87%), histology (tuberculous Lortholary et al.
granuloma with or without necrosis) in 7 patients (10%) and other techniques in 2 patients (3%). The median baseline CD4+ T cell count was 159 (IQR 137 -223) and 70 cells/mm 3 (IQR 20 -142) in patients with isolated pulmonary TB and patients with other TB sites, respectively (Table 1) .
Sixty-two patients (90%) received rifampicin and 7 received other antituberculous drugs (3 because of rifampicin resistance and 4 for other reasons).
Fifty-six (81%) received efavirenz at 800 mg/day and 11 efavirenz at 600 mg/day (most of them not receiving rifampicin); 2 patients did not receive efavirenz (1 lost to follow-up and 1 treated with lopinavir because efavirenz was contraindicated).
Main outcomes
In the ITT analysis, combined success (HIV-1 RNA ,50 copies/mL and TB cure at week 48) was achieved in 57/69 patients (83%, 95% CI 74 -92). TB cure at week 48 was considered definite in 49 patients (71%, 95% CI 60 -82) and probable in 19 patients. The median duration of TB treatment was 11 months (IQR 9 -12). Fifty-seven patients (83%) took TB treatment continuously, while 12 patients interrupted at least one drug. Combined success was obtained in 8 of 9 patients with TB drug resistance. The remaining patient was lost to follow-up at week 48 but was considered cured at the last visit. Among the 47 patients who fully adhered to the trial strategy, combined success was achieved in 45 cases (96%, 95% CI 90 -100). Twenty-two patients did not comply perfectly with the strategy, because of adverse events related to the study drugs (n ¼ 12), virological failure/resistance (n¼ 5), voluntary withdrawal (n¼ 3) or other causes (n¼ 2).
The reasons for failure were HIV-1 RNA .50 copies/mL at week 48 in 12 patients (17%) and TB treatment failure in 1 of them (this patient was lost to follow-up at week 0). Six patients had HIV-1 RNA .400 copies/mL at the last visit, including three patients who discontinued cART.
Virological outcome
Median HIV-1 RNA load fell from 5.4 to 2.6 log 10 copies/mL between weeks 0 and 4, and by a median of 3.5 log 10 copies/mL between weeks 0 and 48 (IQR 24.2 to 22.9). Plasma HIV-1 RNA was ,50 copies/mL in 53%, 79% and 88% of patients at weeks 12, 24 and 48, respectively, with no difference between the two efavirenz dosages (Figure 2a) . One virological failure due to acquired resistance to lamivudine and efavirenz was observed. Median HIV-1 DNA values fell from 3.3 to 2.7 log 10 copies/mL between weeks 0 and 48, with a median decrease of 0.6 log 10 copies/mL (IQR 21.0 to 20.3).
The median increase in the CD4+ T cell count between weeks 0 and 48 was 150 cells/mm 3 (IQR 94 -289) ( Figure 2b ) and was similar in patients with isolated pulmonary TB and those with TB at other sites. Lortholary et al.
Adverse events and safety
Sixty-eight patients (99%) experienced at least one adverse event, including at least one serious adverse event in 31 patients (45%), the latter being attributed to the study drugs in 23 patients.
Among a total of 49 serious adverse events (24 related to study drugs), 11 led to discontinuation of one or both antiretroviral drugs, comprising 4 liver-related events, 4 cases of renal failure, 2 psychiatric events and 1 case of fever with abdominal pain. All Simplified cART and TB 787 JAC were considered related to the study drugs by the investigator and the sponsor and all resolved during the trial. No patient died. The adverse events were neurological (n¼ 43, 16%), cutaneous (n¼19, 7%) or hepatic (n¼12, 4%). Seventy-seven adverse events were considered by the investigator as related to efavirenz (71 clinical, 6 biological). Clinical adverse events related to efavirenz occurred after a median of 26 days (first quartile 6 days). Eightyone percent of neurological and 58% of hepatic adverse events were considered related to efavirenz (Table 2) . Among the 19 patients who discontinued the study regimen, 9 (47%) did so because of efavirenz intolerance (initial dosage 800 mg/day in eight cases, 600 mg/day in one case). These latter adverse effects occurred after a median of 26 days (IQR 16-116) and comprised four neuropsychiatric events, three hepatic events, one case of gynaecomastia and one of IRIS. At the time of efavirenz withdrawal, three of the patients concerned were receiving 600 mg/day.
All seven renal adverse events (four serious) were attributed to tenofovir.
Among the 277 recorded adverse events, 33 (12%) were attributed to TB agents, including 9 hepatic events and 1 cutaneous event.
Impact of the initial efavirenz dosage and therapeutic monitoring
Among the 37 patients receiving efavirenz at 800 mg/day plus rifampicin at week 0 and for whom efavirenz serum concentrations were available at week 2, values were within, above and below the therapeutic range in 26 (71%), 9 (24%) and 2 (5%) patients, respectively. The two patients receiving efavirenz at 600 mg/day plus rifampicin both had efavirenz serum concentrations within the therapeutic range at week 2. Week 2 efavirenz serum concentrations did not differ between patients of African origin and other patients. The increase in the CD4+ T cell count between baseline and week 48 was 209 (IQR 10 -357) and 150 cells/mm 3 (IQR 96 to 230), respectively, in patients with efavirenz plasma concentration .4 mg/L at week 2 (n¼ 11) and patients with lower concentrations (n¼ 34).
Among the 26 patients who experienced neurological adverse effects related to efavirenz, 14, 7 and 2 patients had week 2 serum efavirenz concentrations within, above and below the therapeutic range, respectively, while 3 patients had no available values. Among the nine patients with high efavirenz concentrations at week 2, eight (89%) experienced a related adverse event (neurological, hepatic and cutaneous events in seven, two and one, respectively).
Serial serum concentrations of rifampicin and isoniazid
Rifampicin concentrations at 2 h were often below the expected range of C max values (Table 3) : almost 75% of samples were below the expected range and 50% were ,4 mg/L (data not shown). Median 2 h rifampicin concentrations differed significantly between week 2 (6.0 mg/L; IQR 3.6-8.8) and week 12 (3.8 mg/L; IQR 0.9 -6.0, P,0.03) (Figure 3a) and were significantly lower in males (4.0 mg/L, IQR 2.3 -6.1) than in females (6.0 mg/L, IQR 1.7-9.2) (P,0.04) (Figure 3b ). Neither the degree of immune deficiency nor body weight influenced TB drug pharmacokinetics. Almost 50% of 2 h isoniazid serum concentrations were below the therapeutic range (data not shown), but low concentrations of TB drugs were not associated with TB treatment failure. Lortholary et al.
IRIS
Twenty-three patients (33%) had IRIS (95% CI 22 -44), 19 cases being considered 'definite' according to the French, INSHI (International Network for the Study of HIV IRIS) and ERC classifications. Discrepancies among the three classifications were noted in the remaining four cases. Five episodes (22%) were considered serious (two cases of acute renal failure, two cerebral tuberculomas with seizures or intracranial hypertension, and one case of segmental bronchus compression), and 12 patients (52%) required steroid therapy. The median time between cART initiation and the onset of IRIS was 8 days (IQR 5 -14) . In multivariate analysis, a higher BMI (OR ¼ 0.84 per additional unit, 95% CI 0.71 -0.98, P ¼ 0.03) and a higher haemoglobin level (OR ¼ 0.66 per additional unit, 95% CI 0.45 -0.95, P ¼ 0.02) were protective against IRIS (Table 4) .
Discussion
In the ANRS 129 BKVIR trial, 83% of HIV-infected patients with TB were successfully treated, with tuberculosis cure and HIV viral control at week 48. Our findings thus support UK, EACS (European AIDS Clinical Society) and WHO recommendations advocating first-line tenofovir DF/emtricitabine and efavirenz combination therapy for antiretroviral-naive HIV-infected patients receiving TB drugs. 3, 17 Previous studies of efavirenz combined with other nucleoside analogues have also given encouraging results. 18 -23 Subsequent studies favoured efavirenz rather than nevirapine co-administration with rifampicin. 6 Given the deleterious pharmacokinetic interaction between rifampicin and efavirenz, 24 we initially prescribed efavirenz at 800 mg/day. However, 50% of patients who discontinued the study regimen did so because of efavirenz intolerance, mostly at 800 mg/day, in keeping with British data. 25 The optimal efavirenz dosage for use in combination with rifampicin remains a matter of heated debate. One study showed that ethnicity and low body weight influenced efavirenz concentrations. 26 Earlier studies of slim Thai patients failed to show differences in efavirenz concentrations or efficacy when used with rifampicin. 20, 21 In South Africa, efavirenz at 600 mg/day plus rifampicin was associated with wide variations in efavirenz concentrations and with neurological adverse effects in up to 50% of patients but resulted in good virological outcomes. 27 A more recent study showed that efavirenz concentrations did not decrease after adding rifampicin when 600 mg/day dosage was used, while they increased when 800 mg/day dosage was used. 28 Our data support recommendations advocating efavirenz at 600 mg/day for co-administration with rifampicin, but efavirenz at 800 mg/day remains an option for patients weighing .60 kg, 3, 4 who tend to have lower efavirenz concentrations. 29 A higher risk of treatment failure was found when the efavirenz dose was not adjusted to body weight, 30 but the recent STRIDE study showed no benefit of weight-based dosing. 31 The tenofovir DF/emtricitabine and efavirenz combination tested here, although associated with a high rate of well-known adverse effects (partially due to close observation in the hospital setting), appears to be an acceptable option. Other options, such as nevirapine-containing regimens, could also be acceptable. 32 We found low concentrations of both rifampicin (75% of patients) and isoniazid (50% of patients) in these HIV-infected patients with TB. In four earlier studies, around three-quarters of patients had rifampicin concentrations ,8 mg/L (,4 mg/L in around one-third of cases). 33 -36 In three studies, around 50% of patients had isoniazid concentrations ,3 mg/L. 33, 35, 36 Of note, we found no influence of body weight on rifampicin concentrations, contrary to a recent study of South African patients. 33 Two former studies and the present study showed lower rifampicin concentrations in male patients. 33, 37 Surprisingly, isoniazid plasma levels were also low, whereas HIV serostatus is supposed to have little or no effect on isoniazid concentrations. 38 -40 We found that low rifampicin and isoniazid serum concentrations did not affect TB treatment efficacy. Likewise, Chideya et al. 41 and Burhan et al. 42 only found a relationship between low pyrazinamide concentrations and poorer outcome in Botswana and Indonesia, respectively. Together, these data suggest that routine monitoring of isoniazid and rifampicin concentrations is not mandatory for HIV-infected patients with TB, even though low drug exposure is predictive of poor clinical outcome in all-comer patients with tuberculosis. 43 Twelve percent of adverse events were attributed to TB drugs, including 9/12 hepatic and 1/19 cutaneous events, although it should be noted that recording only started at the time of inclusion and that early TB drug-related adverse effects were therefore Simplified cART and TB 789 JAC missed. The hepatic toxicity of TB drugs is increased by HIV infection 5 and adds to that of NNRTIs. 19, 23, 44 Our results are consistent with those of trials in which at least 90% of surviving TB patients had an undetectable viral load after 1 year of efavirenz combined with nucleoside inhibitors. 45 -47 Using consensus definitions 8, 15 we observed a high rate (33%) of paradoxical but not unmasking IRIS, 8, 48 one-fifth of cases being considered serious. This is in the upper range of values reported in the literature.
16,49 -52 Such a high rate of paradoxical IRIS based on systematic notification strongly suggests that the frequency of subacute IRIS is underestimated in poorer countries, at least outside of clinical trials; for example, the Camelia study showed that IRIS occurred in 26% of HIV-infected patients with TB. 53 A recent meta-analysis suggested that IRIS occurs in 16% of HIV-infected patients with TB. 54 A similarly high concordance between expert opinions, INSHI-2008 and French-2004 IRIS definitions was recently found by Manosuthi et al., 16 but not in other studies. 7, 52 In all HIV-infected patients with active TB, cART is recommended to be initiated in the 2 weeks after TB treatment initiation when CD4+ T cell count is ,50 cells/mm 3 . 4, 45, 46, 55 Half of our patients started cART within 8 weeks after TB treatment initiation and the median time between cART initiation and IRIS onset was 8 days. Only a low BMI and a low haemoglobin level were independently associated with the occurrence of IRIS. We recently showed that early CD4+ T cell activation was predictive of IRIS in the same cohort of patients. 56 Early cART introduction, a low baseline CD4+ T cell count, extrapulmonary TB, high viral load at cART initiation and good immunological and virological responses to cART have been shown elsewhere to be risk factors for IRIS. 16,31,49 -51,53,54,57,58 Finally, we believe that the smaller sample size did not affect the conclusion as the success rate was far higher than expected. Indeed, the confidence interval of 83% ranged from 74% to 92% (i.e. a precision of 9%) and the lower bound (74%) is higher than the estimated upper bound of a confidence interval of 55% with a precision of 10% (i.e. 65%).
In conclusion, our results support the use of tenofovir DF/ emtricitabine/efavirenz (600 mg/day) as first-line therapy for HIV infection in patients with tuberculosis. Lortholary et al.
